~4 spots leftby Oct 2025

Laser Therapy for Foot Ulcers

(LLL&DIAB-02 Trial)

RR
Overseen byRose Raizman, MSc, MScN
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Scarborough Rouge Hospital
Must not be taking: Immunosuppressants
Disqualifiers: Active malignancy, Anemia, Uncontrolled hyperglycemia, others
No Placebo Group
Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests if using the B-cure laser at home can help patients with diabetic foot ulcers heal faster. The laser light is believed to make cells repair and grow quicker, aiding in wound healing. Patients will use the device along with their standard treatment. The laser has been shown to accelerate healing of acute or chronic wounds, and specifically diabetic foot ulcers.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking immunosuppressive medication or have received certain growth factor therapies recently, you may not be eligible to participate.

What data supports the effectiveness of this treatment for foot ulcers?

Research shows that photobiomodulation therapy (PBMT), which includes low-level laser therapy (LLLT), can help heal diabetic foot ulcers by promoting faster healing and reducing the risk of complications. Studies have demonstrated that PBMT is effective in healing chronic wounds, including diabetic foot ulcers, by improving microcirculation and supporting tissue repair.12345

Is laser therapy safe for treating foot ulcers?

Research on low-level laser therapy (also known as photobiomodulation) suggests it is generally safe for humans, as it is used to reduce swelling, inflammation, and promote healing in various conditions, including diabetic foot ulcers.15678

How does the B-Cure Laser Pro treatment differ from other treatments for foot ulcers?

The B-Cure Laser Pro treatment, also known as low-level laser therapy (LLLT), is unique because it uses light to promote healing by improving blood flow and reducing inflammation, which can accelerate the healing of foot ulcers, especially in diabetic patients. Unlike conventional treatments, LLLT is non-invasive and can significantly reduce ulcer size when used alongside standard care.2591011

Research Team

RR

Rose Raizman, MSc, MScN

Principal Investigator

Scarborough Health Network

Eligibility Criteria

This trial is for adults aged 18-95 with Type 1 or Type 2 diabetes and a diabetic foot ulcer that's lasted at least 3 months. They must have good blood flow in their legs and be able to change dressings. Women who can have children must use effective birth control. People with severe anemia, uncontrolled diabetes, recent cancer treatments, or those using immunosuppressants cannot join.

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or Female
See 8 more

Exclusion Criteria

Anemia (Hb<8 gr/dL)
You have a device at home that uses low-level laser therapy.
HbA1c > 12% (uncontrolled hyperglycemia)
See 8 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive standard treatment and self-treat at home daily with either the active B-Cure laser device or a sham device

12 weeks
Visits every 2 weeks for wound evaluation

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • B-Cure Laser Pro (Photobiomodulation)
  • Sham laser (Procedure)
Trial OverviewThe study tests the B-Cure Laser Pro device against a sham laser to see if it speeds up healing of diabetic foot ulcers when used at home along with standard care. Participants will randomly receive either the real or sham treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: B-Cure Laser ProExperimental Treatment1 Intervention
Subjects from the B-Cure Laser Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
Group II: Sham laserPlacebo Group1 Intervention
Subjects from the Sham laser group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.

B-Cure Laser Pro is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as B-Cure Laser Pro for:
  • Diabetic foot ulcers
  • Chronic pain
  • Orthopedic conditions
  • Sports injuries
  • Wounds

Find a Clinic Near You

Who Is Running the Clinical Trial?

Scarborough Rouge Hospital

Lead Sponsor

Trials
4
Recruited
510+

Findings from Research

Photobiomodulation (PBM) therapy, using specific wavelengths of light, has been shown to improve healing rates for diabetic foot ulcers (DFUs) compared to standard wound care, based on a review of 13 studies involving 417 participants.
Despite the positive outcomes, the studies had limitations such as small sample sizes and inconsistencies in laser protocols, indicating a need for further research to solidify PBM's efficacy and optimize treatment parameters.
Photobiomodulation and diabetic foot and lower leg ulcer healing: A narrative synthesis.Sutton, E., Ganie, S., Chan, C., et al.[2021]
In a study involving 23 patients with diabetic foot ulcers, low-level laser therapy (LLLT) significantly reduced ulcer size after 4 weeks compared to a placebo, indicating its potential effectiveness in promoting wound healing.
After 20 weeks, more patients in the LLLT group achieved complete healing (8 out of 13) compared to the placebo group (3 out of 10), suggesting that LLLT may accelerate the healing process for chronic diabetic foot ulcers.
A randomized clinical trial on the effect of low-level laser therapy on chronic diabetic foot wound healing: a preliminary report.Kaviani, A., Djavid, GE., Ataie-Fashtami, L., et al.[2015]
In a placebo-controlled double-blind study involving 10 patients with diabetic foot or chronic leg ulcers, 90% of those treated with broadband visible light (400-800 nm) had their wounds completely closed after 12 weeks, compared to only 33% in the placebo group.
The treatment group experienced an average wound size reduction of 89%, while the placebo group saw only a 54% reduction, indicating that broadband light therapy is a promising and effective option for treating non-healing ulcers.
Visible light-induced healing of diabetic or venous foot ulcers: a placebo-controlled double-blind study.Landau, Z., Migdal, M., Lipovsky, A., et al.[2011]

References

Photobiomodulation and diabetic foot and lower leg ulcer healing: A narrative synthesis. [2021]
A randomized clinical trial on the effect of low-level laser therapy on chronic diabetic foot wound healing: a preliminary report. [2015]
Visible light-induced healing of diabetic or venous foot ulcers: a placebo-controlled double-blind study. [2011]
Effect of Photobiomodulation on Repairing Pressure Ulcers in Adult and Elderly Patients: A Systematic Review. [2021]
Photobiomodulation therapy in neuroischaemic diabetic foot ulcers: a novel method of limb salvage. [2019]
Low-level laser therapy: Case-control study in dogs with sterile pyogranulomatous pododermatitis. [2020]
Management of recurrent aphthous ulcers with therapeutic Nd:YAG laser, using two different methods. [2023]
[Advancement in the research of effect of low level laser therapy on wound healing]. [2015]
Low-level laser therapy as an adjunct to conventional therapy in the treatment of diabetic foot ulcers. [2018]
Efficacy of low-level light therapy for treatment of diabetic foot ulcer: A systematic review and meta-analysis of randomized controlled trials. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
A Systematic Review and Meta-Analysis of the Effects of Low-Level Laser Therapy in the Treatment of Diabetic Foot Ulcers. [2022]